Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?
Over the past 15 years, a significant increase in new HIV/AIDS diagnoses has been observed in the elderly population. This new epidemiological shift has been attributed to a longer sex life, lifestyle and changes in sexual behavior, poor sexual health education, and misconceptions about the absence of sexually transmitted disease in later life. Although many biomedical and behavioral interventions have proven useful to prevent sexually transmitted infections and HIV, pre-exposure prophylaxis (PrEP) has been shown to be the most successful biomedical intervention to prevent HIV in high-risk individuals. This approach is based on delivering a fixed dose of tenofovir disoproxil fumarate (300 mg), alone or combined with emtricitabine (300/200 mg) daily or on demand, before and after sexual intercourse. Despite the consistent number of clinical trials proving the effectiveness and safety of this strategy, no studies have focused specifically on elderly people. These individuals, who may benefit substantially from (PrEP), are at a higher risk of experiencing side effects secondary to tenofovir exposure. This review critically discusses the efficacy and safety of PrEP in people aged over 50 years and translates the knowledge of tenofovir management in patients with HIV into monitoring and stopping rules to be used in this special population. We provide practical recommendations to properly identify PrEP candidates among older adults. Furthermore, we define correct case management before and during PrEP delivery, and we suggest stopping rules and alternative sexually transmitted infection prevention strategies.
Both authors are responsible for the intellectual content, critical revisions, and approval of the manuscript.
Compliance with Ethical Standards
No funding was received for the preparation of this article.
Conflict of interest
Giovanni Guaraldi and Iacopo Franconi have no conflicts of interest directly relevant to the content of this article.
- 2.European AIDS Clinical Society. Guidelines for treatment of HIV-positive adults in Europe. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed 16 Oct 2017.
- 4.World Health Organization. Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. 2012. http://www.who.int/hiv/pub/guidance_prep/en/. Accessed 26 Mar 2018.
- 5.Centers for Disease and Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States: 2014 clinical practice guideline. https://www.cdc.gov/hiv/risk/prep/index.html. Accessed 16 Oct 2017.
- 17.Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection among people who inject drugs in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90. https://doi.org/10.1016/S0140-6736(13)61127-7.CrossRefPubMedGoogle Scholar
- 22.Chen Y, Bussell AS, Shen Z, et al. Declining inconsistent condom use but increasing HIV and syphilis prevalence among older male clients of female sex workers: analysis from sentinel surveillance sites (2010–2015), Guangxi, China. Med (Baltimore). 2016;95(22):e3726. https://doi.org/10.1097/MD.0000000000003726.CrossRefGoogle Scholar
- 24.Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;64(1):79–86. https://doi.org/10.1097/QAI.0b013e31828ece33.CrossRefPubMedGoogle Scholar
- 28.Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba AD. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):1124. https://doi.org/10.1126/scitranslmed.3003174.CrossRefGoogle Scholar
- 31.Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743–6. https://doi.org/10.1093/ndt/gfh658.CrossRefPubMedGoogle Scholar
- 32.Tang EC, Vittinghoff E, Anderson PL, et al. Changes in kidney function associated with daily tenofovir disoproxil fumarate/emtricitabine for HIV preexposure prophylaxis use in the United States Demonstration Project. J Acquir Immun Defic Syndr. 2018;77(2):193–8.Google Scholar
- 41.Gandhi M, Glidden DV, Mayer K, et al. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV. 2016;3(11):e521–8. https://doi.org/10.1016/S2352-3018(16)30153-9.CrossRefPubMedPubMedCentralGoogle Scholar